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Abstract 
Introduction and aims 
The p53 protein is a mediator of the cellular response to DNA damage. The aim of this 
study was to evaluate the predictive and/or prognostic value of p53 expression in relation 
to the molecular subtypes of breast cancer in patients treated with preoperative 
chemotherapy. 
Patients and methods 
Patients with stage II-III breast cancer were included in the study. The expression of p53 
was evaluated by immunohistochemistry on the diagnostic core biopsy specimen. Patients 
received 4–6 courses of preoperative chemotherapy. Pathological complete response 
(pCR) was defined as complete disappearance of invasive tumor in the breast and axillary 
lymph nodes. 
Results 
154 patients were included in the study and the molecular subtypes of their tumors were 
classified as follows: triple negative 18.2%, hormone receptor positive 60.4%, and HER2 
positive 21.4%. p53 was expressed in 43.5% of the patients. A significant association 
between p53 expression and breast cancer molecular subtypes, tumor differentiation, and 
proliferation was observed. pCR was achieved in 8 patients (5.2%). p53 expression, 
molecular subtype, and nuclear grading were significant predictors of pCR (odds ratio for 
pCR in patients with p53-expressing tumors 10.03, p=0.0077). In univariate analysis, the 
expression of p53 as well as high proliferation and lymph node involvement after 
preoperative chemotherapy were predictors of a worse disease-free survival. Patients with 
p53 positivity also had a worse overall survival. In multivariate analysis, both p53 
expression and nodal status after preoperative chemotherapy were significantly associated 
with disease-free and overall survival: the hazard ratios for relapse and death in patients 
with p53-expressing versus non-p53-expressing tumors were 2.29 (p=0.015) and 7.74 
(p=0.002), respectively. The hazard ratios for relapse and death in node-positive versus 
node-negative patients were 3.63 (p=0.003) and 3.64 (p=0.041), respectively. 
Conclusions 
In this series of patients, p53 expression was significantly associated with markers of 
aggressive tumor biology, and with a higher likelihood of attaining pCR. p53 expression 
was a negative prognostic parameter for disease-free and overall survival in univariate and 
multivariate analysis. 
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